Immune checkpoint inhibitors-based therapies for first-line treatment of advanced ovarian cancer with non-BRCAm/HRD-negative: a cost-effectiveness analysis

Key Points

• Cost-effectiveness was assessed for immune checkpoint inhibitors in advanced ovarian cancer.
• The analysis indicated that these therapies could be economically viable options.
• Utilizing recent economic models, the study focused on patients with non-BRCAm and HRD-negative profiles.
• Findings support the idea that effective treatment strategies can also be cost-effective.